Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred between Feb. 15 and March 3. Deal Watch is supported by deal intelligence from Strategic Transactions.
Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline
Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.
